Clinical Phenotype, Treatment Exposure, Treat-to-Target Status, and Longitudinal Outcomes in Juvenile-Onset Systemic Lupus Erythematosus: A Single-Center Retrospective Cohort Study
4 affiliations
- 1Department of Pediatric Rheumatology, Samsun City Hospital, 55080 Samsun, Türkiye
- 2Department of Pediatric Rheumatology, Başakşehir Çam ve Sakura City Hospital, 34480 Istanbul, Türkiye
- 3Department of Pediatric Rheumatology, Samsun University, 55080 Samsun, Türkiye
- 4Department of Pediatric Nephrology, Acibadem Maslak Hospital, 34457 Istanbul, Türkiye
Abstract
Background/Objectives: Treat-to-target assessment is central to the management of juvenile-onset systemic lupus erythematosus (jSLE). We primarily evaluated last-visit childhood lupus low disease activity state (cLLDAS) status and its limiting components, and secondarily described clinical phenotype, treatment exposure, and outcomes. Methods: This retrospective single-center cohort included 54 patients with jSLE followed during 2020–2025; one patient who died 10 days after diagnosis was excluded from last-visit analyses, and the remaining 53 had at least 6 months of follow-up. The Paediatric Rheumatology European Society (PReS)-endorsed cLLDAS definition was applied at the last visit using a retrospectively assigned physician global assessment (PGA). Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and laboratory values at diagnosis and the latest assessment were compared descriptively. Results: Median age at diagnosis was 15.0 years, and median follow-up was 34.6 months (IQR 21.2–70.6). Biopsy-proven lupus nephritis occurred in 29.6% (class IV, 13/16). Median SLEDAI-2K was 8.0 at diagnosis and 4.0 at the latest assessment. At the last visit, 29/53 patients (54.7%; 95% CI 40.4–68.4) were in cLLDAS, and 32/53 (60.4%) met the SLEDAI-2K and glucocorticoid components; of 24 patients outside the target, 17 had SLEDAI-2K > 4 and 7 exceeded the glucocorticoid ceiling (both in 3). Conservative minimum rates of flare, infection-related hospitalization, and intensive care unit admission were 5.6, 5.2, and 1.4 per 100 patient-years, respectively; one early death occurred. Conclusions: Just over half of the patients were in cLLDAS at the last visit, with residual disease activity as the main barrier, followed by glucocorticoid dose. These observational data reflect outcomes within the available follow-up period and cannot establish treatment effectiveness or long-term prognosis.
Related
- Longitudinal trajectories of questionnaire-derived health burden and clinical correlates among community-dwelling older adults: a retrospective cohort study in Deyang, China
- A Large Spanish Cohort Study Defines SCA27B Distinct Clinical Phenotype and its Longitudinal Progression
- Effects of rectal retractor use on dosimetric parameters, treatment-related adverse events, and clinical outcomes of cervical cancer brachytherapy: A retrospective tertiary-centre study
- Comparison Between Systemic Lupus Erythematosus Patients with and Without Family History of Systemic Lupus Erythematosus—A Single-Center Retrospective Study
- Longitudinal Evaluation of Serum Varicella-zoster Virus Viral Load in a Woman with Systemic Lupus Erythematosus Complicated by a Visceral Disseminated Varicella-zoster Virus Infection: A Case Report
BibTeX
@article{yucel2026clinical,
title = {{Clinical Phenotype, Treatment Exposure, Treat-to-Target Status, and Longitudinal Outcomes in Juvenile-Onset Systemic Lupus Erythematosus: A Single-Center Retrospective Cohort Study}},
author = {Burcu Bozkaya Yücel and Şeyda Doğantan and Semanur Elmas and Özlem Aydoğ},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15208004},
url = {https://www.mdpi.com/2077-0383/15/20/8004},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Clinical Phenotype, Treatment Exposure, Treat-to-Target Status, and Longitudinal Outcomes in Juvenile-Onset Systemic Lupus Erythematosus: A Single-Center Retrospective Cohort Study
AU - Burcu Bozkaya Yücel
AU - Şeyda Doğantan
AU - Semanur Elmas
AU - Özlem Aydoğ
PY - 2026
DA - 2026/10/01
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15208004
UR - https://www.mdpi.com/2077-0383/15/20/8004
AB - Background/Objectives: Treat-to-target assessment is central to the management of juvenile-onset systemic lupus erythematosus (jSLE). We primarily evaluated last-visit childhood lupus low disease activity state (cLLDAS) status and its limiting components, and secondarily described clinical phenotype, treatment exposure, and outcomes. Methods: This retrospective single-center cohort included 54 patients with jSLE followed during 2020–2025; one patient who died 10 days after diagnosis was excluded from last-visit analyses, and the remaining 53 had at least 6 months of follow-up. The Paediatric Rheumatology European Society (PReS)-endorsed cLLDAS definition was applied at the last visit using a retrospectively assigned physician global assessment (PGA). Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and laboratory values at diagnosis and the latest assessment were compared descriptively. Results: Median age at diagnosis was 15.0 years, and median follow-up was 34.6 months (IQR 21.2–70.6). Biopsy-proven lupus nephritis occurred in 29.6% (class IV, 13/16). Median SLEDAI-2K was 8.0 at diagnosis and 4.0 at the latest assessment. At the last visit, 29/53 patients (54.7%; 95% CI 40.4–68.4) were in cLLDAS, and 32/53 (60.4%) met the SLEDAI-2K and glucocorticoid components; of 24 patients outside the target, 17 had SLEDAI-2K > 4 and 7 exceeded the glucocorticoid ceiling (both in 3). Conservative minimum rates of flare, infection-related hospitalization, and intensive care unit admission were 5.6, 5.2, and 1.4 per 100 patient-years, respectively; one early death occurred. Conclusions: Just over half of the patients were in cLLDAS at the last visit, with residual disease activity as the main barrier, followed by glucocorticoid dose. These observational data reflect outcomes within the available follow-up period and cannot establish treatment effectiveness or long-term prognosis.
SN - 2077-0383
ER -